T-cell receptor deep sequencing for 40 samples total.
Ended Purchase Order Awarded Last action
- Contract number
- HHSN261201400206P
- Awardee
-
Adaptive Biotechnologies Corporation UEI DMW5BNQ331K9
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $14,275
Award facts
- Contract value 100% obligated
- $14,274.88 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Bethesda, MD 20892, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$0 | |
| Other Administrative Action | -$425 | |
| Original award | $14,700 |
About this award
The National Cancer Institute awarded a purchase order to Adaptive Biotechnologies Corporation for $14,274.88 on March 4, 2014, to perform T-cell receptor deep sequencing on 40 samples total. Performance is located in Bethesda, Maryland. The order is firm fixed price with an ultimate completion date of September 11, 2019.
Quick answers
Who was awarded contract HHSN261201400206P?
HHSN261201400206P was awarded to Adaptive Biotechnologies Corporation by National Cancer Institute (National Institutes of Health) on March 4, 2014.
How much is contract HHSN261201400206P worth?
The government has obligated $14,275 on HHSN261201400206P.
Was contract HHSN261201400206P competed?
The extent of competition for HHSN261201400206P was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award